DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161236

Prevalence of virological failure amongst WHO- defined immunological failure HIV patients on first line of highly active antiretroviral therapy in a tertiary care hospital in Haryana, India

Manisha Rajian, Paramjeet S. Gill, Uma Chaudhary

Abstract


Background: In resource limited settings in India, monitoring of treatment in HIV patients taking highly active antiretroviral therapy is done by six monthly CD4 count instead of highly sensitive plasma viral load. Patients are subjected to viral load only when their CD4 count is low for the last 12 months. This protocol has a huge disadvantage as treatment failure is detected much later than it has actually occurred and switch over to second line therapy gets delayed by approximately one year.

Methods: Plasma viral load (pVL) of 50 WHO defined immunological failure cases was done using RT-PCR to detect virological failure (VF).

Results: Out of 50 WHO defined immunological failure cases, 16 percent had developed virological failure.

Conclusions: Nearly one-sixth of WHO defined immunological failure (IF) cases had developed virological failure. These patients required second line highly active antiretroviral therapy (HAART) therapy but due to following of current treatment monitoring protocol, treatment got delayed by one year. Thus, amendment in national policy for monitoring ART is required to diagnose treatment failure early so that there is no delay in switching to second line ART and morbidity and mortality in these patients can be reduced.

 


Keywords


VF, IF, CD4 count, pVL, HAART

Full Text:

PDF

References


Federal Ministry of Health (FMoH) website. Guideline for management of opportunistic infections andantiretroviral treatment in adolescents and adults in Ethiopia. Available: http://www.who.int/hiv/pub/guidelines/ethiopia_art.pdf. Accessed 2013 Nov 11.

Kanapathipillai R, McGuire M, Mogha R, Szumilin E, Heinzelmann A, et al. Benefit of viralload testing for confirmation of immunological failure in HIV patients treated in rural Malawi. Trop Med IntHealth. 2011;16:1495-500.

WHO website. Antiretroviral Therapy for HIV infection in Adults and Adolescents Recommendations fora public health approach 2010 revision. Available: http://wholibdoc.who.int/ publications/ 2010/ 9789241599764_eng.pdf. Accessed 2013 Dec 9. 12/09/2013.

Deeks SG, Barbour JD, Martin JN, Sanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus. J Infect Dis. 2000;181:946-53.

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med.1997;337:725-33.

Prabhakar B, Banu A, Pavithra B, Chandrashekhra P, Sasthri S, et al. Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. Indian J Sex Transm Dis. 2011;32(2):94-8.

Haubrich RH, Currier JS, Forthall DN, Beall G, Kemper CA, Johnson D, et al. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis. 2001;33: 1060-8.

Petersen ML, van der Laan MJ, Sonia N, Eron JJ, Moore RG, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008;22:2097-106.

Hatano H, Hunt P, Weidler P, Coakley E, Hoh R, Liegler T, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive regimen. Clin Infect Dis. 2006;43:1329-36.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services; Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [cited 2013 Nov 10]. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.

World Health Organization. Geneva, Switzerland: WHO; 2010. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach [2010 revision] [cited 2013 Nov 10]. Available from: http://whqlibdoc.who.int/ publications/ 2010/9789241599764_eng.pdf.

Vallabhaneni S, Chandy S, Heylen E, Ekstrand ML, et al. Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy. J Int AIDS Soc. 2013;16(1):18449.

Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971-7.

Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49:454-62.

Rewari BB, Bachani D, Rajasekaran S, Deshpande A, Chan PL, Srikantiah P. Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. J Acquir Immune Defic Syndr. 2010;55:610-4.

National AIDS Control Organization. Antiretroviral therapy guidelines for HIV infected adults and adolescents including postexposure-2007. [cited 2013 Nov 7]. Available from:http://nacoonline.org/ upload/Policies%20&%20Guidelines/1.%20Antiretroviral%20Therapy%20Guidelines%20for%20HIVInfected%20Adults%20and%20Adolescents%20Including%20Post-exposure.pdf.

Plasma viral load measurement by COBAS® TaqMan® HIV-1 Test, version 2.0 For Use with The High Pure System. Roche Molecular Systems. 11/2012; 05923573001-03 Doc Rev. 3.0.

Robbins GK, Daniels B, Zheng H, Chueh H,Meigs JB,Freedberg KA, et al. Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic. J Acquir Immune Defic Syndr. 2007;44(1):30-7.

Bello EJM, Correia AF, Marin JRP, Merchan-Hamm E, Kanzaki LIB. Predictors of virologic failure in HIV/AIDS treated with highly active antiretroviral therapy in Brasilia, Brazil during 2002-2008. Drug Targets Insights. 2011;5:33-41.

Low-Beer S, Yip B, O’Shaughnessy MV, Hogg RS, MontanerJS, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-1.

Bekker LG, Orrel C, Reader L, Matoti K, Cohen K, Martell R. Antiretroviral therapy in a community clinic – early lessons from a pilot project. A Afr Med J. 2003;93(6):458-62.

Von Reyn CF, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis. 2011;15(8):1087-92.

Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Tiec CL, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infectious Diseases. 2009;9:81.